Prediction method
The method predicts anticancer drug efficacy by integrating cell omics and patient medical information through a three-dimensional cell structure with AI, addressing variations in cancer treatment and drug resistance, thereby improving treatment accuracy and safety.
Patent Information
- Application Number
- JP2024147179
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Filing Date
- 2024-08-29
- Publication Date
- 2024-11-21
- Estimated Expiration
- 2040-06-30
AI Technical Summary
Existing methods for predicting the efficacy of anticancer drugs based solely on cell omics data fail to account for variations in cancer treatment difficulty and progression due to factors like cancer type, stage, and patient medical conditions, leading to deviations in drug effectiveness.
A prediction method using a computer device that considers both cell omics information and additional patient medical information, including a three-dimensional cell structure with cancer cells and stromal cells, to evaluate anticancer drug efficacy, incorporating immune cells and vascular networks, and utilizing AI for supervised learning to predict drug effectiveness.
Accurately predicts the efficacy of anticancer drugs by considering patient-specific factors, allowing for personalized treatment plans and anticipating drug resistance, enhancing treatment effectiveness and safety.
Smart Images

Figure 2024163138000001_ABST
Abstract
Description
[Technical field]
[0001] The present invention relates to a prediction method. [Background technology]
[0002] There are technologies that use signal processing technology to support treatment for patients. For example, Patent Document 1 discloses a technology that determines the effectiveness of treatment by administering a drug to a patient based on the correlation between omics data of diseased cells collected from the patient and sensitivity to the drug (hereinafter also referred to as drug efficacy).
[0003] There are also methods for evaluating the efficacy of drugs in cells ex vivo (outside the living body). For example, Patent Document 2 discloses a method for evaluating the anticancer effect of an anticancer drug by culturing cancer cells in the presence of immune cells and an anticancer drug. In Patent Document 2, the anticancer drug is administered to a three-dimensional cell structure that coexists with the stroma that coexists with the cancer cells in the living body, such as endothelial cells and fibroblasts, making it possible to evaluate the effect on the cancer cells that exist in a state closer to that of the living body than cells grown on a flat surface.
[0004] If the technology of Patent Document 1 is applied to the cell structure described in Patent Document 2, it will be possible to more accurately determine the effectiveness of treatment for patients by using the results of evaluating drug efficacy under conditions closer to those in the living body. [Prior art documents] [Patent documents]
[0005] [Patent Document 1] Special Publication No. 2016-528565 [Patent Document 2] International Publication No. 2019 / 039452 Summary of the Invention [Problem to be solved by the invention]
[0006] However, when it comes to cancer treatment, the difficulty of treatment and the degree of cancer progression vary greatly depending on the type of cancer, stage, patient age, and other symptoms. For this reason, as in Patent Document 1, there is a high possibility that the usefulness of drug administration considering only omics data of cells may deviate from the effectiveness of drugs actually administered to cancer patients.
[0007] The present invention has been made in consideration of the above circumstances, and aims to provide a prediction method capable of predicting the efficacy of an anticancer drug by taking into account not only omics information of cells but also other information related to the patient's condition. [Means for solving the problem]
[0008] The prediction method of the present invention is a prediction method performed by a computer device that predicts anti-cancer effects, in which an input information acquisition unit acquires input information including information about cancer in a subject to be predicted and drug information of an anti-cancer drug for which the effect on the subject is to be estimated, and a prediction unit predicts the possibility that cancer cells in the subject corresponding to the input information will acquire resistance to the anti-cancer drug using a correspondence between information about cancer in unspecified subjects and the drug information of the anti-cancer drug, and information indicating whether the subject's cancer cells have acquired resistance to the anti-cancer drug, which is obtained by administering the anti-cancer drug to cells collected from the subject. Effect of the Invention
[0009] According to the present invention, it is possible to predict the efficacy of an anticancer drug by taking into consideration not only omics information of cells but also other information related to the patient's condition. [Brief description of the drawings]
[0010] [Figure 1] 1 is a block diagram showing an example of the configuration of an anticancer agent effect evaluation system 1 according to an embodiment of the present invention. [Diagram 2] 1 is a block diagram showing an example of the configuration of a learning device 60 according to an embodiment of the present invention. [Diagram 3] FIG. 2 is a block diagram showing an example of the configuration of a prediction device 70 according to an embodiment of the present invention. [Figure 4] FIG. 6 is a diagram showing an example of the configuration of state information 620 according to an embodiment of the present invention. [Diagram 5] FIG. 6 is a diagram showing an example of the configuration of omics information 621 according to an embodiment of the present invention. [Figure 6] FIG. 6 is a diagram showing an example of the configuration of drug information 622 according to an embodiment of the present invention. [Figure 7] FIG. 13 is a diagram showing an example of the configuration of drug information 622A according to an embodiment of the present invention. [Figure 8] FIG. 13 is a diagram showing an example of the configuration of administration record information 623 according to an embodiment of the present invention. [Figure 9] FIG. 13 is a diagram showing an example of the configuration of drug effectiveness information 624 according to the embodiment of the present invention. [Figure 10] 1 is a sequence chart showing a flow of processes performed by an anticancer agent effect evaluation system 1 according to an embodiment of the present invention. [Figure 11] 4 is a flowchart showing the flow of processing performed by a learning device 60 according to an embodiment of the present invention. [Figure 12] 4 is a flowchart showing the flow of processing performed by a prediction device 70 according to an embodiment of the present invention. [Figure 13] 4 is a flowchart showing the flow of processing performed by a prediction device 70 according to an embodiment of the present invention. [Figure 14] 4 is a flowchart showing the flow of processing performed by a prediction device 70 according to an embodiment of the present invention. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0011] Hereinafter, an embodiment of the present invention will be described with reference to the drawings.
[0012] The anticancer drug effectiveness evaluation system 1 is a system that uses AI (artificial intelligence) technology to predict which anticancer drugs are effective against a patient's cancer cells. The patient in this case is a patient to whom an anticancer drug is administered in cancer treatment, and is an example of a "subject."
[0013] In the anticancer drug effectiveness evaluation system 1, the results of evaluating the anticancer effects of anticancer drugs acting on cancer cells in unspecified subjects are treated as so-called big data. In the anticancer drug effectiveness evaluation system 1, a trained model (a prediction model described later) that has been subjected to supervised learning using the big data is used to predict which anticancer drugs will be effective against the patient's cancer cells.
[0014] In this embodiment, the anticancer effect of an anticancer agent acting on cancer cells in a subject is evaluated ex vivo (outside the living body). Specifically, a three-dimensional cell structure containing cancer cells collected from a subject may be cultured in the presence of a single anticancer drug, a combination of immune cells and an anticancer drug, or a combination of multiple anticancer drugs to evaluate the anticancer effect of the single anticancer drug, the combination of immune cells and an anticancer drug, or a combination of multiple anticancer drugs. In this embodiment and this specification, the term "anticancer drug" may include a single anticancer drug, a combination of multiple anticancer drugs, and a combination of immune cells and an anticancer drug. The three-dimensional cell structure here is a cell that has a three-dimensional structure and in which cancer cells exist in a state closer to the environment of cancer cells in a living body than cells grown in a two-dimensional state. The three-dimensional cell structure may be, for example, a cell structure organized in a state in which cancer cells collected from a subject coexist with interstitium that coexists with the cancer cells in the environment in a living body, such as endothelial cells and fibroblasts. As a three-dimensional cell structure, for example, the cell structure described in Patent Document 2 is suitable. By using the evaluation results of the evaluation using the three-dimensional cell structure, it is possible to obtain a more reliable evaluation of the anticancer effect of the anticancer drug.
[0015] In this embodiment and the present specification, the "three-dimensional cell structure" may be a three-dimensional structure in which multiple cell layers are stacked. The "cell layer" refers to a layer composed of a group of cells and stroma that exist in a direction perpendicular to the thickness direction and in which the cell nuclei do not overlap in the thickness direction when observed at a magnification at which the cell nuclei can be recognized in a slice image of a cross section of the cell structure in the thickness direction, that is, at a magnification at which the entire thickness of the stained slice is in the field of view. In addition, "layered" means that two or more different cell layers are stacked in the thickness direction. The three-dimensional cell structure used in this embodiment is constructed by cells that constitute the stroma and cancer cells. The cells that constitute the stroma may or may not include immune cells.
[0016] The interstitial cells and cancer cells constituting the three-dimensional cell structure according to the present embodiment are not particularly limited, and may be cells collected from an animal, cells obtained by culturing cells collected from an animal, cells obtained by subjecting cells collected from an animal to various treatments, or cultured cell lines. In the case of cells collected from an animal, the site of collection is not particularly limited, and the cells may be somatic cells derived from bone, muscle, internal organs, nerves, brain, bone, skin, blood, etc., germ cells, or embryonic stem cells (ES cells). In addition, the species from which the cells constituting the three-dimensional cell structure according to the present embodiment are derived is not particularly limited, and cells derived from animals such as humans, monkeys, dogs, cats, rabbits, pigs, cows, mice, and rats can be used. The cells cultured from cells collected from an animal may be primary culture cells or subculture cells. In addition, the cells subjected to various treatments include induced pluripotent stem cells (iPS cells) and cells after differentiation induction. The cancer cells are preferably cells collected from an animal, and more preferably primary culture cells. Furthermore, the three-dimensional cell structure according to this embodiment may be composed only of cells derived from the same biological species, or may be composed of cells derived from multiple types of biological species.
[0017] Examples of interstitial cells include endothelial cells, fibroblasts, nerve cells, mast cells, epithelial cells, cardiomyocytes, hepatocytes, pancreatic islet cells, tissue stem cells, smooth muscle cells, etc. The interstitial cells contained in the three-dimensional cell structure according to this embodiment may be of one type or of two or more types. The type of interstitial cells contained in the three-dimensional cell structure according to this embodiment is not particularly limited, and can be appropriately selected in consideration of the origin and type of the cancer cells to be contained, the type of immune cells to be used for evaluation, the type of anticancer agent to be used for evaluation, the in vivo environment in which the desired anticancer activity is exerted, etc.
[0018] A vascular network is important for the proliferation and activity of cancer cells. For this reason, the three-dimensional cell structure according to this embodiment is preferably one that includes a vascular network. In other words, the three-dimensional cell structure according to this embodiment is preferably one in which a vascular network is constructed three-dimensionally inside, constructing a tissue that is closer to that in a living body. The vascular network may be formed only inside the cell structure, or may be formed so that at least a part of the vascular network is exposed on the surface or bottom surface of the cell structure. In this embodiment and this specification, the term "vascular network" refers to a net-like structure having multiple branches, such as a vascular network in a living tissue.
[0019] The vascular network can be formed by including endothelial cells that constitute blood vessels as interstitial cells. The endothelial cells included in the three-dimensional cell structure according to this embodiment may be vascular endothelial cells. When the three-dimensional cell structure according to this embodiment is provided with a vascular network, the cells other than the endothelial cells in the three-dimensional cell structure are preferably cells that constitute the tissue surrounding blood vessels in a living body, since endothelial cells are likely to form a vascular network that maintains its original function and shape, and are more preferably cells that include at least fibroblasts as the cells other than the endothelial cells, since they are more likely to resemble the cancer microenvironment in a living body, and are even more preferably cells that include vascular endothelial cells and fibroblasts. The cells other than the endothelial cells included in the three-dimensional cell structure may be cells derived from the same biological species as the endothelial cells, or may be cells derived from a different biological species.
[0020] Examples of cancers from which the cancer cells to be included in the three-dimensional cell structure according to this embodiment are derived include breast cancer (e.g., invasive ductal carcinoma, non-invasive ductal carcinoma, inflammatory breast cancer, etc.), prostate cancer (e.g., hormone-dependent prostate cancer, hormone-independent prostate cancer, etc.), pancreatic cancer (e.g., pancreatic ductal carcinoma, etc.), gastric cancer (e.g., papillary adenocarcinoma, mucinous adenocarcinoma, adenosquamous carcinoma, etc.), lung cancer (e.g., non-small cell lung cancer, small cell lung cancer, malignant mesothelioma, etc.), colon cancer (e.g., gastrointestinal stromal tumor, etc.), rectal cancer (e.g., gastrointestinal stromal tumor, etc.), colon cancer (e.g. familial colorectal cancer, hereditary nonpolyposis colorectal cancer, gastrointestinal stromal tumor, etc.), small intestine cancer (e.g. non-Hodgkin's lymphoma, gastrointestinal stromal tumor, etc.), esophageal cancer, duodenal cancer, tongue cancer, pharyngeal cancer (e.g. nasopharyngeal cancer, oropharyngeal cancer, hypopharyngeal cancer, etc.), head and neck cancer, salivary gland cancer, brain tumors (e.g. pineal astrocytoma, pilocytic astrocytoma, diffuse astrocytoma, anaplastic astrocytoma, etc.), neurilemmoma, liver cancer (e.g. primary liver cancer, extrahepatic bile duct cancer, etc.) , kidney cancer (e.g., renal cell carcinoma, transitional cell carcinoma of the renal pelvis and ureter, etc.), gallbladder cancer, bile duct cancer, pancreatic cancer, liver cancer, endometrial cancer, cervical cancer, ovarian cancer (e.g., epithelial ovarian cancer, extragonadal germ cell tumor, ovarian germ cell tumor, ovarian low malignant potential tumor, etc.), bladder cancer, urethral cancer, skin cancer (e.g., intraocular (eye) melanoma, Merkel cell carcinoma, etc.), hemangioma, malignant lymphoma (e.g., reticulum cell sarcoma, lymphosarcoma, Hodgkin's disease, etc.), melanoma, thyroid cancer (e.g., medullary thyroid cancer, etc.), parathyroid These include, but are not limited to, cancer, nasal cancer, paranasal sinus cancer, bone tumors (e.g., osteosarcoma, Ewing's tumor, uterine sarcoma, soft tissue sarcoma, etc.), metastatic medulloblastoma, angiofibroma, dermatofibrosarcoma protuberans, retinal sarcoma, penile cancer, testicular tumor, pediatric solid tumors (e.g., Wilms' tumor, pediatric renal tumor, etc.), Kaposi's sarcoma, Kaposi's sarcoma caused by AIDS, maxillary sinus tumor, fibrous histiocytoma, leiomyosarcoma, rhabdomyosarcoma, chronic myeloproliferative disorder, leukemia (e.g., acute myeloid leukemia, acute lymphoblastic leukemia, etc.), and the like.
[0021] The three-dimensional cell structure according to this embodiment may be a structure in which cancer cells are scattered throughout the structure, or may be a structure in which cancer cells are present only in a specific cell layer. In the three-dimensional cell structure according to this embodiment, when cancer cells are present only in a specific cell layer, the position of the cell layer (cancer cell layer) containing these cancer cells in the structure is not particularly limited. When the three-dimensional cell structure is cultured in the presence of an anticancer drug, the anticancer effect can be evaluated, including the ability of the anticancer drug to infiltrate and reach the cancer cells in the structure, by providing a cancer cell layer not on the top surface of the structure but inside the structure.
[0022] The above-mentioned three-dimensional cell structure may be produced by the manufacturing method described in Patent Document 2. The manufacturing method described in Patent Document 2 comprises the following steps (a) to (c): (a) a step of mixing cells and an extracellular matrix component in a cationic buffer solution to obtain a mixture, (b) a step of seeding the mixture obtained in step (a) in a cell culture vessel, and (c) a step of obtaining a cell structure in which cells are stacked in multiple layers in the cell culture vessel after step (b).
[0023] Examples of the cationic buffer include Tris-HCl buffer, Tris-maleic acid buffer, Bis-Tris buffer, HEPES, etc. The concentration and pH of the cationic substance in the cationic buffer (e.g., Tris in Tris-HCl buffer) are not particularly limited as long as they do not adversely affect cell growth and the construction of cell structures.
[0024] Examples of the strong electrolyte polymer include, but are not limited to, glycosaminoglycans such as heparin, chondroitin sulfate (e.g., chondroitin 4-sulfate, chondroitin 6-sulfate), heparan sulfate, dermatan sulfate, keratan sulfate, and hyaluronic acid; dextran sulfate, rhamnan sulfate, fucoidan, carrageenan, polystyrene sulfonic acid, polyacrylamide-2-methylpropane sulfonic acid, and polyacrylic acid, or derivatives thereof. The mixture prepared in step (a) may contain only one type of strong electrolyte polymer, or may contain a combination of two or more types.
[0025] Examples of the extracellular matrix components include collagen, laminin, fibronectin, vitronectin, elastin, tenascin, entactin, fibrillin, proteoglycan, or modified or variant thereof. Examples of proteoglycan include chondroitin sulfate proteoglycan, heparan sulfate proteoglycan, keratan sulfate proteoglycan, dermatan sulfate proteoglycan, etc. The mixture prepared in step (a) may contain only one type of extracellular matrix component, or may contain a combination of two or more types.
[0026] In this embodiment, the anticancer drug acting on cancer cells may be any drug used in cancer treatment, and may include not only drugs that act directly on cancer cells, such as cytotoxic drugs, but also drugs that do not have cytotoxicity but suppress the proliferation of cancer cells. Examples of anticancer drugs that do not have cytotoxicity include drugs that do not directly attack cancer cells, but rather suppress the proliferation of cancer cells, slow down the activity of cancer cells, or kill cancer cells by acting cooperatively with immune cells or other drugs in the body, and drugs that suppress the proliferation of cancer cells by damaging cells or tissues other than cancer cells. The anticancer drug used in this embodiment may be a drug known to have an anticancer effect, or may be a candidate compound for a novel anticancer drug (new drug).
[0027] Examples of cytotoxic anticancer agents include, but are not limited to, molecular targeted drugs, alkylating agents, metabolic antagonists such as 5-FU anticancer agents, plant alkaloids, anticancer antibiotics, platinum derivatives, hormones, topoisomerase inhibitors, microtubule inhibitors, and compounds classified as biological response modifiers.
[0028] Examples of anticancer drugs that do not have cytotoxicity include, but are not limited to, angiogenesis inhibitors, prodrugs of anticancer drugs, drugs that regulate intracellular metabolic enzyme activity related to the metabolism of anticancer drugs or their prodrugs (hereinafter referred to as "intracellular enzyme regulators" in the specification), immunotherapeutic agents, etc. In addition, drugs that ultimately participate in anticancer action by enhancing the function of anticancer drugs or improving immune function in the body are also included.
[0029] The angiogenesis inhibitor may be any compound that is expected to have angiogenesis inhibitory activity, and may be a known angiogenesis inhibitor or a candidate compound for a novel angiogenesis inhibitor. Known angiogenesis inhibitors include Avastin, EYLEA, Suchibaga, CYRAMZA (registered trademark) (Eli Lilly, also known as ramucirumab), BMS-275291 (Bristol-Myers), Celecoxib (Pharmacia / Pfizer), EMD121974 (Merck), Endostatin (EntreMed), Erbitaux (ImCloneSystems), Interferon-α (Roche), LY317615 (Eli Lilly), Neovastat (Aeterna), and the like. Laboratories), PTK787 (Abbott), SU6688 (Sugen), Thalidomide (Celgene), VEGF-Trap (Regeneron), Iressa (registered trademark) (Astrazeneca, also known as gefitinib), Caplerusa (registered trademark) (Astrazeneca, also known as pandetanib), Recentin (registered trademark) (Astrazeneca, also known as cediranib), VGX-100 (Circadian Technologies), VD1andcVE199, VGX-300 (Circadian Technologies), sVEGFR2, hF4-3C5, Nexavar (registered trademark) (Bayer Examples of such anti-NRP2B drugs include those manufactured by Takeda Yakuhin, also known as sorafenib), Vortrient (registered trademark) (manufactured by GlaxoSmithKline, also known as pazopanib), Sutent (registered trademark) (manufactured by Pfizer, also known as sunitinib), Inlyta (registered trademark) (manufactured by Pfizer, also known as axitinib), CEP-11981 (manufactured by Teva Pharmaceutical Industries), AMG-386 (manufactured by Takeda Yakuhin, also known as trebananib), anti-NRP2B (manufactured by Genentech), Ofev (registered trademark) (manufactured by Boehringer-Ingelheim, also known as nintatenib), and AMG706 (manufactured by Takeda Yakuhin, also known as motesanib).
[0030] Prodrugs of anticancer drugs are drugs that are converted into active forms with anticancer effects by intracellular enzymes in organs such as the liver and in cancer cells. The cytokine network increases the enzymatic activity of intracellular enzymes, increasing the amount of the active form and enhancing the antitumor effect, so they are considered to be drugs involved in anticancer effects.
[0031] An example of an intracellular enzyme regulator is gimeracil, which does not have a direct antitumor effect when used alone, but is involved in anticancer activity by inhibiting the enzyme that breaks down 5-FU anticancer drugs (dihydropyrimidine dehydrogenase: DPD).
[0032] Immunotherapeutic agents are drugs that obtain anti-cancer effects by improving immune function through activation of immune function or motility of immune cells, etc. Examples of immunotherapeutic agents include drugs used in biological response modifier therapy (hereinafter abbreviated as "BRM preparations"), cytokine-based preparations formed from cytokines secreted from immune cells and involved in migration and infiltration, cancer immune checkpoint inhibitors, cancer vaccines, cancer viruses, etc. Examples of BRM preparations include krestin, lentinan, OK-432, etc. Examples of cytokine-based preparations include interleukins such as IL-8 and IL-2; interferons such as IFN-α, IFN-β, IFN-γ; and chemokines such as CCL3, CCL4, CCL5, CXCL9, CXCL10, CXCL11, CXCL16 / CXCR6, CX3CL1 / CX3CR1, etc.
[0033] Cancer immune checkpoint inhibitors are substances that specifically inhibit the function of proteins that are present on the surface of cancer cells and immune cells and are involved in the reduction of immune function against cancer cells. Examples of such proteins include PD-1, PD-L1, PD-L2, CD4, CD8, CD19, CD28, CD80 / 86, B7, Galectin-9, HVEM, CTLA-4, TIM-3, BTLA, MHC-II, LAG-3, and TCR. As cancer immune checkpoint inhibitors, specific monoclonal antibody drugs against these are preferred. Specifically, examples of cancer immune checkpoint inhibitors include Nivolumab (Opdivo), Pembrolizumab (Keytruda), Atezolizumab (Tecentriq), Ipilimumab (Yervoy), Tremelimumab, durvalmab, and avelumab.
[0034] Immune cells are cells involved in immunity. Specific examples include lymphocytes, macrophages, dendritic cells, etc. Lymphocytes include T cells, B cells, NK cells, plasma cells, etc.
[0035] The immune cells used in this embodiment may be one type or two or more types. The immune cells used in this embodiment are not particularly limited as long as they are immune cells, but are preferably cells that are actually present around the cancer microenvironment and are involved in the mechanism of attacking cancer cells by immune reaction. Specifically, in this embodiment, it is preferable to use one or more types selected from the group consisting of white blood cells and lymphocytes as the immune cells, and it is more preferable to include T cells.
[0036] As the immune cells, PBMC (peripheral blood mononuclear cells in plasma) can be used. PBMCs include lymphocytes and monocytes. Monocytes include macrophages. Lymphocytes include NK cells, B cells, and T cells. In addition to PBMCs, these components can be used alone or in combination. PBMCs may be isolated and purified from blood, but buffy coats prepared from blood can also be used as they are. PBMCs are contained in the buffy coat together with other components. Buffy coats can be prepared from blood by a conventional method such as centrifugation. There may be multiple types of immune cells that have slightly different properties even though they have the same components, such as ABO blood types. In this embodiment, any one type of immune cell may be used, or multiple types of immune cells may be used in combination, as necessary.
[0037] The immune cells may be immune cells collected from a living body, may be cultured cell lines, or may be cells artificially modified or altered in vitro. When immune cells collected from a cancer patient are used, it is preferable to use immune cells isolated from the peripheral blood or tumor site of the cancer patient, particularly PBMCs. In addition, as the artificially modified or altered immune cells, immune cells whose immune function has been artificially altered to enhance anti-cancer activity are preferable. Examples of such immune cells whose immune function has been altered include altered T cells used in gene-modified T cell therapy using chimeric antigen receptors (CARs).
[0038] 1 is a block diagram showing a configuration example of an anticancer drug effect evaluation system 1 according to an embodiment of the present invention. The anticancer drug effect evaluation system 1 includes, for example, an imaging device 10, a determination device 20, a patient information DB 30, a drug information DB 40, and an evaluation system 50. The imaging device 10 is communicatively connected to the determination device 20. The determination device 20, the patient information DB 30, and the drug information DB 40 are communicatively connected to the evaluation system 50.
[0039] The imaging device 10 is a camera that captures an image of a three-dimensional cell structure as a target for evaluating the anticancer effect of an anticancer drug. The imaging device 10 periodically captures images of the culture process in the three-dimensional cell structure cultured in the presence of immune cells and an anticancer drug. The imaging device 10 transmits image information (image data) of the captured three-dimensional cell structure to the determination device 20. Note that, although the above description has been given by way of example of a case in which the culture process is captured periodically, that is, at regular time intervals, the present invention is not limited to this. The imaging device 10 may capture images of the culture process at a specific timing. The specific timing may be a timing preset in the imaging device 10, or may be any timing determined by an imaging technician who captures images using the imaging device 10.
[0040] The determination device 20 is a computer device such as a cloud device, a server device, or a PC (personal computer). The determination device 20 includes, for example, a communication unit, a storage unit, and a control unit. The communication unit communicates with the imaging device 10 and the evaluation system 50. The storage unit stores variables, various data, programs, etc. required to realize the functions of the determination device 20. The control unit evaluates the anticancer effect of the anticancer agent using an image of the three-dimensional cell structure acquired from the imaging device 10 via the communication unit.
[0041] For example, when the cancer cells contained in the three-dimensional cell structure are labeled with a fluorescent substance, the control unit determines whether or not each pixel in the region where the three-dimensional cell structure is imaged is stained with fluorescence based on the RGB value of each pixel in the image, etc. Alternatively, when the image is captured with a resolution that allows individual cells to be identified, such as by capturing an image through a microscope, the control unit may count the number of cells stained with fluorescence.
[0042] The control unit uses the results of analyzing the image to determine whether or not there is an anti-cancer effect. For example, the control unit determines that the anti-cancer agent has an anti-cancer effect if the ratio of the area stained with fluorescence to the area of the entire three-dimensional cell structure is reduced compared to before the anti-cancer agent was administered. Alternatively, the control unit may determine that there is an anti-cancer effect if the number of cancer cells (the number of cells stained with fluorescence) is reduced compared to before the anti-cancer agent was administered. Alternatively, the control unit may determine that there is an anti-cancer effect if a phenomenon suggesting a reduction in the number of cancer cells, such as a reduction in the vascular network, is identified from the image.
[0043] Furthermore, when it is determined that there is an anticancer effect, the control unit may determine the degree of the anticancer effect. For example, the control unit determines the degree of the anticancer effect as a number of levels, such as high, normal, or low, depending on the number of days required for the cancer cells to decrease by a predetermined percentage (e.g., 50%) or more. The control unit notifies the evaluation system 50 via the communication unit of information indicating the anticancer drug administered to the three-dimensional cell structure, the determination result of the presence or absence of the anticancer effect, and the degree of the anticancer effect if there is an anticancer effect, as administration record information 623 or drug effectiveness information 624 described later.
[0044] In the above, the case where the determination device 20 notifies the evaluation system 50 of information on the anticancer effect, etc., has been described as an example, but the present invention is not limited thereto. The evaluation system 50 is only required to acquire information on at least the anticancer effect, etc. For example, the information on the anticancer effect, etc. may be determined by an external device other than the determination device 20, or by a person in charge of follow-up observation, etc. The information on the anticancer effect, etc. may be manually input by an input operation by a person in charge, etc. In this case, it is possible to omit the imaging device 10 and the determination device 20 in the anticancer agent effect evaluation system 1.
[0045] The patient information DB30 is a DB (database) that stores information about patients including subjects, and is, for example, a computer device such as a cloud device, a server device, or a PC (personal computer). The patient information DB30 includes, for example, a communication unit, a storage unit, an input unit, and a control unit. The communication unit communicates with the evaluation system 50. The storage unit stores variables, various data, programs, and the like required to realize the functions of the patient information DB30. The storage unit stores information about the patient. The information about the patient may be any information, and includes, for example, information about cells collected from the patient (omics information 621 described later) and information indicating the state of cancer in the patient (state information 620 described later). The input unit acquires information input via an input device such as a keyboard. The input unit acquires, for example, information about the patient, and stores the acquired information in the storage unit. The control unit notifies the evaluation system 50 of the information about the patient stored in the storage unit via the communication unit.
[0046] The drug information DB40 is a DB that stores information about anticancer drugs (drugs), and is a computer device such as a cloud device, a server device, or a PC. The drug information DB40 includes, for example, a communication unit, a storage unit, an input unit, and a control unit. The communication unit communicates with the evaluation system 50. The storage unit stores variables, various data, programs, and the like required to realize the functions of the drug information DB40. The storage unit stores information about anticancer drugs. The information about anticancer drugs may be any information, and includes, for example, information indicating the structural formula, pharmacology, physical properties, and the like of the drug (drug information 622 described later). The input unit acquires information input via an input device such as a keyboard. The input unit acquires, for example, information about anticancer drugs, and stores the acquired information in the storage unit. The control unit notifies the evaluation system 50 of the information about anticancer drugs stored in the storage unit via the communication unit.
[0047] The evaluation system 50 includes, for example, a learning device 60 and a prediction device 70. The learning device 60 and the prediction device 70 are both computer devices such as a cloud device, a server device, or a PC.
[0048] The learning device 60 generates a prediction model by performing supervised learning on the learning model. The prediction model here is a model that predicts the anticancer effect when an anticancer drug is administered to a patient based on information such as the state of the patient's cancer. The prediction device 70 uses the prediction model generated by the learning device 60 to predict the anticancer effect when an anticancer drug is administered to a patient.
[0049] 2 is a block diagram showing a configuration example of a learning device 60 according to an embodiment of the present invention. The learning device 60 includes, for example, a communication unit 61, a storage unit 62, and a control unit 63. The communication unit 61 communicates with external devices. The external devices here are the determination device 20, the patient information DB 30, the drug information DB 40, and the prediction device 70.
[0050] The storage unit 62 is configured by an HDD (Hard Disk Drive), a flash memory, an EEPROM (Electrically Erasable Programmable Read Only Memory), a RAM (Random Access read / write Memory), a ROM (Read Only Memory), or any combination of these storage media. The storage unit 62 stores, for example, status information 620, omics information 621, drug information 622, administration record information 623, drug effectiveness information 624, and prediction model information 625.
[0051] The status information 620 is information indicating the status of cancer in the subject. The status information 620 is composed of all or part of the information about the patient transmitted from the patient information DB 30 to the evaluation system 50. The omics information 621 is information about cancer cells collected from the subject. The omics information 621 is composed of all or part of the information about the patient transmitted from the patient information DB 30 to the evaluation system 50. The drug information 622 is information about anticancer drugs. The drug information 622 is composed of information about anticancer drugs transmitted from the drug information DB 40 to the evaluation system 50. The administration record information 623 is information indicating the administration record of anticancer drugs administered to cancer cells collected from the subject. The administration record information 623 is composed of information about anticancer drugs administered to the three-dimensional cell structure transmitted from the determination device 20 to the evaluation system 50.
[0052] The drug effectiveness information 624 is information indicating the anticancer effect of the anticancer drug administered to the cancer cells collected from the subject. The information indicating the anticancer effect may include information indicating whether the anticancer drug is effective against the cancer cells or not, information indicating the degree of effectiveness, and information indicating whether the cancer cells have acquired resistance to the anticancer drug. The drug effectiveness information 624 is composed of, for example, a determination result of the presence or absence of an anticancer effect transmitted from the determination device 20 to the evaluation system 50. However, without being limited thereto, the drug effectiveness information 624 may be composed of not only the determination result by the determination device 20 but also the result of a human evaluation based on the result of drug administration. The prediction model information 625 is information indicating a prediction model generated by the learning device 60.
[0053] The control unit 63 is realized, for example, by causing a CPU (Central Processing Unit) provided as hardware in the learning device 60 to execute a program stored in the storage unit 62. The control unit 63 includes, for example, a learning information acquisition unit 630, a preprocessing unit 631, a learning unit 632, and a device control unit 633.
[0054] The learning information acquisition unit 630 acquires learning information. The learning information is information used for learning when performing supervised learning. The learning information is, for example, state information 620, omics information 621, administration record information 623, and drug efficacy information 624. The learning information acquisition unit 630 acquires these pieces of learning information by referring to the storage unit 62, and outputs the acquired learning information to the preprocessing unit 631.
[0055] The preprocessing unit 631 performs pre-processing (pre-processing) for performing supervised learning. Specifically, the preprocessing unit 631 generates a learning dataset. The learning dataset is a combination of learning data and teacher data. The preprocessing unit 631 sets the subject's condition information 620, omics information 621, administration record information 623, and drug information 622 of the anticancer drug administered to the subject's cancer cells as learning data. The preprocessing unit 631 sets the subject's drug effectiveness information 624 corresponding to the learning data as teacher data. The preprocessing unit 631 generates the learning dataset by combining the learning data and the teacher data.
[0056] The learning unit 632 generates a prediction model by performing supervised learning on the learning model using a learning data set. The learning model here is, for example, a deep learning model using a CNN (Convolutional Neural Network) or the like. In the following, a case where the learning model is a CNN will be described as an example, but the present invention is not limited to this. The learning model may be a model applied to existing machine learning, such as a DCNN (Deep CNN), a decision tree, a hierarchical Bayesian model, or a SVM (Support Vector Machine).
[0057] The learning unit 632 inputs the learning data in the learning data set to the learning model. The learning unit 632 adjusts the parameters of the learning model using a method such as the backpropagation method so that the output of the learning model obtained by inputting the learning data (predicted value of effect) approaches the teacher data (actual value of effect) corresponding to the learning data. The learning unit 632 performs supervised learning on the learning model by adjusting the parameters of the learning model so that the output of the learning model obtained by inputting the learning data approaches the teacher data for each of the prepared learning data sets. The learning unit 632 ends the learning of the learning model when it is determined that a predetermined end condition is satisfied. The predetermined end condition is, for example, a condition that the number of learning times reaches a predetermined number of times or the error of the predicted value is equal to or less than a predetermined threshold. The learning unit 632 sets the learning model at the time of ending the learning as the prediction model. The learning unit 632 stores the parameters set in the learning model (prediction model) at the time of ending the learning in the prediction model information 625. The parameters here are variables for generating a predictive model, such as information indicating the number of units in each layer of the CNN's input layer, intermediate layer, and output layer, the number of hidden layers, activation functions, etc., as well as information indicating the coupling coefficients and weights that couple the nodes in each layer.
[0058] The device control unit 633 performs overall control of the learning device 60. The device control unit 633 stores information such as state information 620 acquired via the communication unit 61 in the storage unit 62. In addition, the device control unit 633 transmits information related to the prediction model generated by the learning unit 632 to the prediction device 70 via the communication unit 61.
[0059] 3 is a block diagram showing an example of a configuration of a prediction device 70 according to an embodiment of the present invention. The prediction device 70 includes, for example, a communication unit 71, a storage unit 72, and a control unit 73. The communication unit 71 communicates with an external device. The external device here is the learning device 60.
[0060] The storage unit 72 is configured by an HDD, a flash memory, an EEPROM, a RAM, a ROM, or any combination of these storage media. The storage unit 72 stores, for example, subject information 720, target drug information 721, and prediction model information 722.
[0061] The subject information 720 is information on a subject who is the subject of prediction using a prediction model. The subject information 720 is, for example, information corresponding to the condition information 620 and the omics information 621 on the subject. The subject information 720 is composed of information on the patient transmitted from the patient information DB 30 to the evaluation system 50. Alternatively, the subject information 720 may be composed of information on the subject input from an input unit (not shown) of the prediction device 70 via an input device such as a keyboard.
[0062] The target drug information 721 is information on an anticancer drug (target drug) that is the target of prediction using a prediction model. The target drug information 721 is, for example, information corresponding to the drug information 622 on an anticancer drug that can be administered to a subject. The target drug information 721 is composed of information on a patient transmitted from the drug information DB 40 to the evaluation system 50. Alternatively, the target drug information 721 may be composed of information on a target drug input from an input unit of the prediction device 70 via an input device such as a keyboard.
[0063] The prediction model information 722 is information indicating the prediction model generated by the learning device 60, and is similar to the prediction model information 625.
[0064] The control unit 73 is realized, for example, by causing a CPU provided as hardware in the prediction device 70 to execute a program stored in the storage unit 72. The control unit 73 includes, for example, an input information acquisition unit 730, a prediction target acquisition unit 731, a preprocessing unit 732, a prediction unit 733, a postprocessing unit 734, and a device control unit 735.
[0065] As described above, the prediction device 70 uses a prediction model to make predictions regarding treatment using an anticancer drug. Specifically, the control unit 73 makes predictions for the following prediction targets (1) to (7).
[0066] (1) The degree of anticancer effect when an anticancer drug is administered to the subject's cancer cells (2) The possibility that the subject's cancer cells will acquire resistance to the administered anticancer drugs (3) The degree of anticancer effect of another anticancer drug when the other anticancer drug is administered to cancer cells that have acquired resistance as described in (2). (4) The possibility that the target drug will effectively act on cancer cells (5) Patients who may benefit from the target drug (6) Cancer types for which the target drug may be effective (7) The extent of the anticancer effect of the combination of the target drugs
[0067] In addition, in the prediction targets (1) to (6), the drug administered to the subject or the target drug may be a combination of multiple drugs rather than a single drug. (7) is used when comparing the effect of using a certain drug (including a combination of multiple drugs) with the effect of combining a certain drug with another drug (including a combination of multiple drugs). In addition, the above-mentioned "combination of drugs" includes a "combination of an anticancer drug and an anticancer drug" and a "combination of immune cells and an anticancer drug."
[0068] Which of the prediction targets (1) to (7) is to be the prediction target is determined by, for example, a user's selection. Specifically, a prediction target acquisition unit 731 of the control unit 73 acquires information indicating the prediction target input from an input unit of the prediction device 70 via an input device such as a keyboard. Based on the information indicating the prediction target acquired by the prediction target acquisition unit 731, the control unit 73 controls the input information acquisition unit 730, the pre-processing unit 732, the prediction unit 733, and the post-processing unit 734 to perform prediction using a prediction model. Below, a method for predicting each of the prediction targets (1) to (7) will be described in order.
[0069] First, a method for predicting the prediction target (1) will be described. The input information acquisition unit 730 acquires input information corresponding to the prediction target acquired by the prediction target acquisition unit 731. The input information is information to be input to a prediction model. When the prediction target (1) is a target to be predicted, the input information acquisition unit 730 acquires subject information 720 as input information. The input information acquisition unit 730 outputs the acquired subject information 720 to the preprocessing unit 732.
[0070] The preprocessing unit 732 performs pre-processing (pre-processing) for making predictions using a prediction model. Specifically, when the prediction target (1) is a target to be predicted, the preprocessing unit 732 generates input data in which information on an anticancer drug that can be administered to a subject is associated with the subject information 720. The input data is data to be input to the prediction model when making a prediction.
[0071] The information on the anticancer drug here includes, for example, information on the anticancer drug that can be administered to the subject, and information indicating the dosage. The information on the anticancer drug may be set arbitrarily, but is preferably set to be the same as the content learned by the prediction model (the anticancer drug and its dosage present in the learning data) or within a similar range. This makes it possible to accurately predict the level of the anticancer effect based on the content learned by the prediction model. The preprocessing unit 732 outputs the generated input data to the prediction unit 733.
[0072] The prediction unit 733 predicts the prediction target (1) using a prediction model. The prediction unit 733 acquires prediction model information 722 by referring to the storage unit 72, and constructs a prediction model based on the acquired information. The prediction unit 733 inputs input data generated by the pre-processing unit 732 to the constructed prediction model. The prediction unit 733 acquires an output from the prediction model by inputting the input data to the prediction model. Here, the information output from the prediction model is information indicating the degree of anti-cancer effect when the anti-cancer drug indicated in the input data is administered to the cancer cells of the subject under the input conditions indicated in the input data. The input conditions here are, for example, conditions specified by the state of cancer in the subject specified by the subject information 720, the omics information of the cancer cells of the subject, and the drug information and dosage of the anti-cancer drug for which administration is being considered set by the pre-processing unit 732. The prediction unit 733 outputs the information output from the prediction model to the post-processing unit 734.
[0073] The post-processing unit 734 generates a prediction result of the prediction target (1) based on the information output from the prediction model acquired from the prediction unit 733. For example, when the information indicating the degree of anticancer effect output from the prediction model is equal to or greater than a predetermined threshold, the post-processing unit 734 generates a prediction result indicating that administration of the anticancer drug indicated in the input data to the cancer cells of the subject will be effective. The post-processing unit 734 outputs the generated prediction result to the device control unit 735.
[0074] The device control unit 735 comprehensively controls the prediction device 70. For example, the device control unit 735 stores information such as the prediction model information 625 acquired via the communication unit 71 in the storage unit 72. In addition, the device control unit 735 may display the prediction result generated by the post-processing unit 734 on, for example, a display unit (not shown) of the prediction device 70.
[0075] Next, a method for predicting the prediction target (2) will be described. The flow of processing performed by the input information acquisition unit 730, the preprocessing unit 732, the prediction unit 733, and the postprocessing unit 734 is similar to that in predicting the prediction target (1), and therefore will not be described. In the following, only the configuration in predicting the prediction target (2) that is different from that in predicting the prediction target (1) will be described.
[0076] When predicting the prediction target (2), the prediction unit 733 uses a prediction model trained to predict the prediction target (2). Specifically, a prediction model that predicts the possibility that the cancer cells of the subject will acquire resistance to the anticancer drug indicated in the input data is used. In this case, for example, when generating a prediction model, the learning device 60 uses drug effectiveness information 624 as teacher data that includes information indicating whether the cancer cells of the subject have acquired resistance to the administered anticancer drug. The learning device 60 adjusts the parameters of the model so that the output obtained by inputting the learning data into the learning model approaches the teacher data associated with the learning data, that is, the actual result of whether resistance has been acquired. This makes it possible to generate a prediction model that predicts the possibility that the cancer cells of the subject will acquire resistance to the anticancer drug indicated in the input data.
[0077] In addition, whether or not the three-dimensional cell structure has acquired resistance to the anticancer drug is determined based on the progress of the three-dimensional cell structure after the administration of the anticancer drug to the three-dimensional cell structure. The criterion for determining whether or not the three-dimensional cell structure has acquired resistance to the anticancer drug may be the same as the criterion by the determination device 20, or may be a criterion different from that of the determination device 20. For example, when the determination is performed using the determination device 20, the determination device 20 determines whether or not the three-dimensional cell structure has acquired resistance to the anticancer drug based on the imaging result of the imaging device 10. On the other hand, when the determination is performed without using the determination device 20, whether or not the three-dimensional cell structure has acquired resistance to the anticancer drug is determined by a human visually inspecting the progress of the three-dimensional cell structure after the administration of the anticancer drug.
[0078] The prediction model predicting the prediction target (2) may be the same as the prediction model predicting the prediction target (1) or may be a separate model. When the prediction model predicting the prediction target (1) is the same as the prediction model predicting the prediction target (1), the prediction model predicts the possibility that the anticancer drug indicated in the input data is effective against the cancer cells of the subject as well as the possibility that the cancer cells of the subject will acquire resistance to the anticancer drug indicated in the input data.
[0079] The prediction unit 733 predicts the prediction target (2) using a prediction model. By inputting input data into the prediction model, the output obtained from the prediction model is information indicating the possibility that the cancer cells of the subject will acquire resistance to the anticancer drug indicated in the input data under the input conditions indicated in the input data.
[0080] The post-processing unit 734 generates a prediction result of the prediction target (2) based on the information output from the prediction model acquired from the prediction unit 733. For example, when the information indicating the possibility of acquiring resistance output from the prediction model is equal to or greater than a predetermined threshold, the post-processing unit 734 generates a prediction result indicating that the cancer cells of the subject are highly likely to acquire resistance to the anticancer drug indicated in the input data.
[0081] Next, a method for predicting the prediction target (3) will be described. The flow of processing performed by the input information acquisition unit 730, the preprocessing unit 732, the prediction unit 733, and the postprocessing unit 734 is the same as that in predicting the prediction target (1), and therefore the description thereof will be omitted. In the following, only the configuration in predicting the prediction target (3) that is different from that in predicting the prediction target (1) will be described.
[0082] When predicting the prediction target (3), the prediction unit 733 uses a prediction model trained to predict the prediction target (3). Specifically, a prediction model is used that predicts the degree of anticancer effect of a certain anticancer drug when another anticancer drug is administered to cancer cells that have acquired resistance to the certain anticancer drug. In this case, for example, when generating a prediction model, the learning device 60 uses administration record information 623 as learning data that includes information indicating whether or not the administration is performed after the cancer cell has acquired resistance to the certain anticancer drug. The learning device 60 adjusts the parameters of the model so that the output obtained by inputting the learning data into the learning model approaches the teacher data associated with the learning data, that is, the record of whether or not the administration after the cancer cell has acquired resistance was effective. This makes it possible to generate a prediction model that predicts the degree of anticancer effect acting on cancer cells after the cancer cell has acquired resistance.
[0083] The prediction unit 733 predicts the prediction target (3) using a prediction model. By inputting input data into the prediction model, the output obtained from the prediction model is information indicating the degree to which an anticancer drug indicated in the input data will be effective when administered under input conditions indicated in the input data after the cancer cells of the subject have acquired resistance.
[0084] The post-processing unit 734 generates a prediction result of the prediction target (3) based on the information output from the prediction model acquired from the prediction unit 733. For example, when the information output from the prediction model indicating the degree of anticancer effect by administration after resistance acquisition is equal to or greater than a predetermined threshold, the post-processing unit 734 generates a prediction result indicating that there is a high possibility that the administration of the anticancer drug indicated in the input data will be effective after the cancer cells of the subject have acquired resistance.
[0085] Next, a method for predicting the prediction target (4) will be described. In the following, only the configuration for predicting the prediction target (4) that is different from the configuration for predicting the prediction target (1) will be described.
[0086] When the prediction target (4) is a target to be predicted, the input information acquisition unit 730 acquires, as input information, target drug information 721. The input information acquisition unit 730 outputs the acquired target drug information 721 to the preprocessing unit 732.
[0087] When the prediction target (4) is a target to be predicted, the preprocessing unit 732 generates input data associated with information on a patient to which an anticancer drug corresponding to the target drug information 721 can be administered. The information on the patient here is, for example, condition information indicating the state of cancer in the patient, or information corresponding to omics information such as genetic information of the patient's cancer cells.
[0088] The prediction unit 733 predicts the prediction target (4) using a prediction model. The prediction unit 733 obtains an output from the prediction model by inputting input data into the prediction model. Here, the information output from the prediction model is information indicating the degree of anticancer effect when the target anticancer drug is administered to a patient who meets the input conditions indicated in the input data under the input conditions indicated in the input data.
[0089] The post-processing unit 734 generates a prediction result of the prediction target (4) based on the information output from the prediction model acquired from the prediction unit 733. For example, when the information indicating the degree of anticancer effect output from the prediction model is equal to or greater than a predetermined threshold, the post-processing unit 734 generates a prediction result indicating that the target anticancer drug is effective against cancer cells.
[0090] Next, a method for predicting the prediction target (5) will be described. The flow of the processing performed by the input information acquisition unit 730, the pre-processing unit 732, the prediction unit 733, and the post-processing unit 734 is similar to that in predicting the prediction target (4), and therefore the description thereof will be omitted. Below, only the configurations in predicting the prediction target (5) that are different from those in predicting the prediction target (4) will be described.
[0091] The post-processing unit 734 generates a prediction result for the prediction target (5) based on the information output from the prediction model acquired from the prediction unit 733. For example, the post-processing unit 734 aggregates information indicating the degree of anti-cancer effect output from the prediction model for each cancer state of the patient. For example, when the degree of anti-cancer effect in a group of patients whose cancer states can be considered to be equivalent is equal to or greater than a predetermined threshold, the post-processing unit 734 generates a prediction result indicating that an anti-cancer drug is effective for patients with that cancer state. In other words, it predicts patients for whom an anti-cancer drug may be effective.
[0092] Next, a method for predicting the prediction target (6) will be described. The flow of the processing performed by the input information acquisition unit 730, the pre-processing unit 732, the prediction unit 733, and the post-processing unit 734 is similar to that in predicting the prediction target (4), and therefore the description thereof will be omitted. Below, only the configurations in predicting the prediction target (6) that are different from those in predicting the prediction target (4) will be described.
[0093] The post-processing unit 734 generates a prediction result for the prediction target (6) based on the information output from the prediction model acquired from the prediction unit 733. For example, the post-processing unit 734 aggregates the information indicating the degree of anticancer effect output from the prediction model by cancer type. For example, when the degree of anticancer effect for the same cancer type is equal to or greater than a predetermined threshold, the post-processing unit 734 generates a prediction result for each cancer type indicating that the anticancer drug is effective for that cancer type.
[0094] Next, a method for predicting the prediction target (7) will be described. The flow of the processes performed by the input information acquisition unit 730, the pre-processing unit 732, the prediction unit 733, and the post-processing unit 734 is the same as that in predicting the prediction target (4), and therefore the description thereof will be omitted. Below, only the configurations in predicting the prediction target (7) that are different from those in predicting the prediction target (4) will be described.
[0095] When predicting the prediction target (7), the prediction unit 733 uses a prediction model trained to predict the prediction target (7). Specifically, a prediction model that predicts the degree of anticancer effect by combining target drugs is used. In this case, for example, when generating a prediction model, the learning device 60 uses administration record information 623 as learning data that includes information indicating the combination of administered anticancer drugs. The learning device 60 adjusts the parameters of the model so that the output obtained by inputting the learning data into the learning model approaches the teacher data associated with the learning data, that is, the record of whether or not the administration of the combination of anticancer drugs was effective. This makes it possible to generate a prediction model that predicts the degree of anticancer effect by combining target drugs.
[0096] The prediction unit 733 predicts the prediction target (7) using a prediction model. By inputting input data into the prediction model, the output obtained from the prediction model is information indicating the degree of anticancer effect by administering the target drugs in combination under the input conditions indicated in the input data.
[0097] The post-processing unit 734 generates a prediction result of the prediction target (7) based on the information output from the prediction model acquired from the prediction unit 733. For example, when the information indicating the degree of anticancer effect output from the prediction model is equal to or greater than a predetermined threshold, the post-processing unit 734 generates a prediction result indicating that the anticancer effect will be high when the target drugs are administered in combination.
[0098] FIG. 4 is a diagram showing an example of the configuration of status information 620 according to an embodiment of the present invention. The status information 620 is generated for each subject. The status information 620 includes items such as a subject ID and status information. The subject ID is information that uniquely identifies the subject. The status information includes items such as a stage, age, cancer type, treatment history, pathological findings, and pathological findings. The stage is the stage of the cancer of the subject identified by the subject ID. The age is the age of the subject. The cancer type is the type of cancer of the subject. The treatment history indicates the history of the cancer treatment of the subject. The pathological findings indicate pathological findings such as the test results and diagnosis results of the subject. Examples of the pathological findings include blood test results, urine test results, and interview results. The pathological findings indicate findings such as the results of tests and diagnoses performed on specimens prepared from organs and tissues collected from the subject. Examples of the pathological findings include atypia and pleomorphism of cells in the specimen, the presence or absence and morphology of a tubular structure, and the presence or absence of cell infiltration into interstitial tissue.
[0099] FIG. 5 is a diagram showing an example of the configuration of omics information 621 according to an embodiment of the present invention. The omics information 621 is generated for each subject. The omics information 621 is obtained, for example, by genetically analyzing cells such as blood collected from the subject. The omics information 621 includes items such as a subject ID and omics information. The subject ID is information that uniquely identifies the subject. The omics information includes items such as genomics, transcriptomics, metabolomics, proteomics, and the presence or absence of methylation. Genomics is genetic information of the subject. Transcriptomics is genetic information for each tissue and cell of the subject. Metabolomics is metabolite information of the subject. Proteomics is information related to the subject's proteins. Phenomics is information indicating the phenotype of the subject. The presence or absence of methylation is information indicating the presence or absence of DNA methylation in the subject's cancer cells.
[0100] FIG. 6 is a diagram showing an example of the configuration of drug information 622 according to an embodiment of the present invention. Drug information 622 is generated for each anticancer drug. Drug information 622 includes, for example, a drug ID and drug information. The drug ID is information that uniquely identifies an anticancer drug. The drug information includes items such as structural formula information, pharmacological information, and physical property information. The structural formula information is information that indicates the structural formula of the anticancer drug identified by the drug ID. The pharmacological information is information that indicates physiological changes caused by the anticancer drug. The physical property information is information that indicates the physical properties of the anticancer drug.
[0101] 7 is a diagram showing an example of the configuration of drug information 622A according to an embodiment of the present invention. The drug information 622A is a modified example of the drug information 622, and is generated for each combination when, for example, a plurality of anticancer drugs are administered in combination. The drug information 622A includes, for example, a drug combination ID and drug combination information. The drug combination information is information indicating a combination of anticancer drugs specified by the drug combination ID, and includes, for example, items such as a drug ID of combination 1, which is a first anticancer drug, and a drug ID of combination 2, which is a second anticancer drug.
[0102] FIG. 8 is a diagram showing an example of the configuration of the administration record information 623 according to an embodiment of the present invention. The administration record information 623 is generated for each subject. The administration record information 623 includes items such as a subject ID, administration record information 1, administration record information 2, ..., etc. The subject ID is information that uniquely identifies the subject. The administration record information 1, administration record information 2, ... are information indicating the administration history of the anticancer drug administered to the subject identified by the subject ID. Each administration record information includes items such as a drug ID, dosage, and resistance. The drug ID is information that uniquely identifies the anticancer drug administered to the cancer cells of the subject. The dosage is the amount of the anticancer drug administered to the cancer cells of the subject, and the resistance is information regarding the resistance of the cancer cells of the subject at the time when the anticancer drug was administered. The resistance includes items such as, for example, presence / absence, anticancer drug name, and administration timing. Presence / absence is information indicating the presence or absence of resistance. The anticancer drug name is the name of the anticancer drug to which resistance is provided. The administration timing is information indicating whether the administration is performed after resistance has been acquired or before resistance has been acquired.
[0103] FIG. 9 is a diagram showing an example of the configuration of the drug effectiveness information 624 according to an embodiment of the present invention. The drug effectiveness information 624 is generated for each subject. The drug effectiveness information 624 is generated in response to the administration results shown in the administration results information 623, for example. The drug effectiveness information 624 includes items such as a subject ID and drug effectiveness information 1, 2, .... The subject ID is information that uniquely identifies the subject. The drug effectiveness information 1, 2, ... is information indicating the history of the effect of the anticancer drug administered to the subject identified by the subject ID. Each piece of drug effectiveness information includes items such as administration results information, effect level, and whether or not resistance has been acquired. The administration results information is information indicating the anticancer drug administered to the subject, and is information specified, for example, by administration results information 1, administration results information 2, ..., etc. of the administration results information 623. The effectiveness level is information indicating the degree of effectiveness when the anticancer drug is effective. The effectiveness level may be binary information indicating whether the anticancer drug is effective or not, or may be information indicating the degree of effectiveness of the anticancer drug in multiple stages. The presence or absence of acquired resistance is information indicating whether or not the cancer cells of the subject have acquired resistance to an anticancer drug.
[0104] Fig. 10 is a sequence chart showing the flow of processing performed by the anticancer drug effect evaluation system 1 according to the embodiment of the present invention. Fig. 10 shows the flow of processing for acquiring learning information for learning a learning model in the learning stage.
[0105] A three-dimensional cell structure is constructed from cells collected from a subject (step S10). Specifically, a three-dimensional cell structure is constructed containing cells constituting the interstitium and cancer cells collected from the subject. An anticancer drug is administered to the three-dimensional cell structure (step S11). Specifically, the three-dimensional cell structure is cultured in the presence of the anticancer drug. Information regarding the anticancer drug administered to the three-dimensional cell structure is input to the determination device 20 via an input device such as a keyboard.
[0106] The judgment device 20 stores information about the anticancer drug administered to the three-dimensional cell structure (step S12), and notifies the evaluation system 50 of the information about the anticancer drug administered to the three-dimensional cell structure (step S13). The information about the anticancer drug administered to the three-dimensional cell structure is stored in the memory unit 62 of the learning device 60 as administration history information 623.
[0107] The imaging device 10 images the three-dimensional cell structure (step S14). The imaging device 10 images the three-dimensional cell structure, for example, before administering an anticancer drug to the three-dimensional cell structure and at a predetermined time interval (for example, once a day) after administering the anticancer drug. The imaging device 10 outputs the image of the captured three-dimensional cell structure to the determination device 20 (step S15).
[0108] The determination device 20 determines the anti-cancer effect based on the image of the three-dimensional cell structure acquired from the imaging device 10 (step S16). In this case, the determination device 20 may determine whether the cancer cells of the subject have acquired resistance to the anti-cancer drug. For example, the determination device 20 refers to the administration history information 623 of the subject and determines whether the same drug as the drug to be determined this time has been administered to the subject in the past. If the drug has been administered to the subject in the past and has been determined to have an anti-cancer effect, and the current anti-cancer effect determination result indicates "ineffective", the determination device 20 determines that the cancer cells of the subject have acquired resistance to the anti-cancer drug. On the other hand, if the drug administered to the subject in the past has been determined to have an anti-cancer effect and the current anti-cancer effect determination result also indicates "effective", the determination device 20 determines that the cancer cells of the subject have not acquired resistance to the anti-cancer drug. The determination device 20 notifies the evaluation system 50 of the determination result (step S17). This determination result is stored in the memory unit 62 of the learning device 60 as drug effectiveness information 624.
[0109] Meanwhile, the subject's genes and the like are investigated from cells (blood) collected from the subject (step S18). The investigation results regarding the subject's genes and the like are input to the patient information DB 30 via an input device such as a keyboard.
[0110] The patient information DB30 stores the results of the investigation into the genes, etc. of the subject (step S19), and notifies the evaluation system 50 of information indicating the investigation results (steps S20, S21). Of the information indicating the results of the investigation into the genes, etc. of the subject, information indicating the state of the cancer, such as the stage and age of the subject, is stored as state information 620 in the storage unit 62 of the learning device 60. In addition, information indicating the results of the investigation into the genes, etc. of the cancer cells of the subject is stored as omics information 621 in the storage unit 62 of the learning device 60.
[0111] Meanwhile, information regarding the anticancer drug is input to the drug information DB 40 via an input device such as a keyboard, and is stored in the drug information DB 40 (step S22). The drug information DB 40 notifies the evaluation system 50 of the information regarding the anticancer drug (step S23). This information regarding the anticancer drug is stored in the memory unit 62 of the learning device 60 as drug information 622.
[0112] Fig. 11 is a flow diagram showing the flow of processing performed by the learning device 60 according to an embodiment of the present invention. Fig. 11 shows the flow of processing in which the learning device 60 creates a prediction model. The learning device 60 acquires learning data and teacher data (step S31). Specifically, the learning device 60 acquires condition information 620, omics information 621, administration record information 623, and drug information 622 on the subject as learning data. The learning device 60 acquires drug effectiveness information 624 on the subject as teacher data.
[0113] The evaluation system 50 generates a learning dataset by combining the learning data and the teacher data (step S32). The learning device 60 inputs the learning data from the learning dataset to the learning model (step S33). The learning device 60 adjusts the parameters of the learning model so that the difference between the output obtained from the learning model and the teacher data from the dataset becomes small (step S34). The learning device 60 determines whether a predetermined learning end condition is satisfied (step S35). If the learning end condition is satisfied, the learning device 60 determines the learning model at that time as a prediction model and stores the parameter values set in the model as prediction model information 625. On the other hand, if the learning end condition is not satisfied in step S35, the learning device 60 returns to step S33 and repeats learning.
[0114] 12 to 14 are flow diagrams showing the flow of processing performed by the prediction device 70 according to an embodiment of the present invention. Fig. 12 shows the flow of processing in which the prediction device 70 predicts any one of the prediction targets (1) to (3). Note that the flow diagram in Fig. 12 is based on the premise that a prediction model capable of predicting any one of the prediction targets (1) to (3) has already been created by the learning device 60, and information indicating the prediction model (prediction model information 722) has been stored in the prediction device 70.
[0115] The prediction device 70 acquires subject information 720 of the subject as input information (step S41). The prediction device 70 sets information on the anticancer drug for predicting the anticancer effect in association with the input information (step S42). The information on the anticancer drug here is information indicating, for example, drug information, dosage, administration timing, etc. of the anticancer drug. The administration timing is information indicating whether the drug is administered before or after resistance is acquired.
[0116] The prediction device 70 inputs the subject information 720 acquired in step S41 and the information regarding the anticancer drug set in step S42 into a prediction model, and predicts the anticancer effect of the set anticancer drug from the obtained output (step S43).
[0117] The prediction device 70 judges whether or not the anticancer effects of all anticancer drugs for which the anticancer effects are to be predicted have been predicted (step S44). If there is an anticancer drug for which the anticancer effects have not yet been predicted, the prediction device 70 returns to step S42 and makes a prediction.
[0118] In step S44, when the prediction device 70 has already predicted the anticancer effects for all anticancer drugs, it determines which of prediction targets (1) to (3) the prediction target is (step S45), generates a prediction result according to the prediction target, and outputs the generated result.
[0119] When the subject to be predicted is the prediction subject (1), the prediction device 70 outputs a prediction result indicating that an anticancer drug having an anticancer effect equal to or greater than a predetermined threshold is an anticancer drug that is effective against the subject's cancer cells (step S46).
[0120] When the subject to be predicted is the prediction subject (2), the prediction device 70 outputs a prediction result indicating that an anticancer drug for which the possibility of acquiring resistance is equal to or greater than a predetermined threshold is an anticancer drug to which the subject's cancer cells are likely to acquire resistance (step S47).
[0121] When the subject to be predicted is the prediction subject (3), the prediction device 70 outputs a prediction result indicating that an anticancer drug whose anticancer effect when administered after resistance has been acquired is equal to or greater than a predetermined threshold value is an anticancer drug that is effective when administered after the subject's cancer cells have acquired resistance (step S48).
[0122] 13 shows a process flow in which the prediction device 70 predicts any one of the prediction targets (4) to (6). Here, it is assumed that a prediction model capable of predicting any one of the prediction targets (4) to (6) has been created by the learning device 60, and information indicating the prediction model (prediction model information 722) has been stored in the prediction device 70.
[0123] The prediction device 70 acquires target drug information 721 as input information (step S51). The prediction device 70 sets information about a patient to be administered an anticancer drug in association with the input information (step S52). The information about the patient here is, for example, information indicating the patient's condition information, omics information, etc.
[0124] The prediction device 70 inputs the target drug information 721 acquired in step S51 and the information about the patient set in step S52 into a prediction model, and predicts the anti-cancer effect of the anti-cancer drug corresponding to the target drug information 721 from the obtained output (step S53).
[0125] The prediction device 70 judges whether or not the anticancer effects of all anticancer drugs for which the anticancer effects are to be predicted have been predicted (step S54). If there is an anticancer drug for which the anticancer effects have not yet been predicted, the prediction device 70 returns to step S52 and makes a prediction.
[0126] When the prediction target is prediction target (4), the prediction device 70 outputs a prediction result indicating that an anticancer drug having an anticancer effect equal to or greater than a predetermined threshold is an anticancer drug that is effective against cancer cells (step S55).
[0127] When the subject to be predicted is the prediction subject (5), the prediction device 70 compiles the anticancer effects for each patient condition, and outputs prediction results indicating, for each patient condition, anticancer drugs whose anticancer effects are equal to or greater than a predetermined threshold when administered to a group of patients with similar cancer conditions, and anticancer drugs that are effective when administered (step S56).
[0128] When the subject to be predicted is the prediction subject (6), the prediction device 70 tallyes up the anticancer effects by cancer type, and outputs prediction results indicating, for each cancer type, anticancer drugs whose anticancer effects are equal to or greater than a predetermined threshold when administered to a group of the same cancer type, and anticancer drugs that are effective when administered (step S57).
[0129] 14 shows a process flow for predicting a prediction target (7) by the prediction device 70. Here, it is assumed that a prediction model capable of predicting any of the prediction targets (7) has been created by the learning device 60, and information indicating the prediction model (prediction model information 722) has been stored in the prediction device 70.
[0130] The prediction device 70 acquires subject information 720 on a subject as input information (step S61). The prediction device 70 sets information on a combination of anticancer drugs for predicting an anticancer effect in association with the input information (step S62).
[0131] The prediction device 70 inputs the subject information 720 acquired in step S61 and information regarding the combination of anticancer drugs set in step S62 into a prediction model, and predicts the anticancer effect of the combination of anticancer drugs set from the obtained output (step S63).
[0132] The prediction device 70 judges whether or not the anticancer effects of all combinations of anticancer drugs for which the anticancer effects are to be predicted have been predicted (step S64). If there is still a combination of anticancer drugs for which the anticancer effects have not been predicted, the prediction device 70 returns to step S62 and makes a prediction.
[0133] In step S64, if the prediction device 70 has already predicted the anti-cancer effects for all combinations of anti-cancer drugs for which the anti-cancer effects are to be predicted, it outputs a prediction result indicating that administering a combination of anti-cancer drugs whose anti-cancer effects are equal to or greater than a predetermined threshold will be effective against the subject's cancer cells (step S65).
[0134] As described above, the evaluation system 50 of the embodiment is an evaluation system for evaluating an anticancer effect, and includes a learning information acquisition unit 630, a learning unit 632, a memory unit 72, an input information acquisition unit 730, and a prediction unit 733. The learning information acquisition unit 630 acquires learning data and teacher data. The learning data is information about cancer in unspecified subjects, and includes at least the state information 620. The teacher data is information about the effect of an anticancer drug obtained by administering the anticancer drug to cells collected from the subject. The learning unit 632 generates a prediction model. The prediction model is a model that makes predictions about treatment using an anticancer drug. The learning unit 632 generates a prediction model by having the learning model learn the correspondence between the learning data and the teacher data acquired by the learning information acquisition unit 630 in a supervised manner. The memory unit 72 stores the prediction model generated by the learning unit 632. The input information acquisition unit 730 acquires input information. The input information is information about cancer in a subject to be predicted. The prediction unit 733 uses the input information and the prediction model to make predictions regarding treatment using an anticancer drug. The learning information acquisition unit 630 acquires, as teacher data, information regarding the anticancer effect obtained by administering an anticancer drug to the three-dimensional cell structure. The three-dimensional cell structure is a structure containing cancer cells collected from an unspecified subject and cells that constitute the interstitium.
[0135] As a result, the evaluation system 50 of the embodiment can use the subject's condition information 620 as learning data and generate a prediction model for predicting anticancer effects in consideration of the subject's cancer condition. Therefore, it becomes possible to evaluate the efficacy of an anticancer drug in consideration of not only omics information of cells but also cancer condition information, which is various information on the patient.
[0136] In addition, in the evaluation system 50 of this embodiment, information on the anticancer effect obtained by administering an anticancer drug to a three-dimensional cell structure is acquired as teacher data, so that a prediction model can be generated that has learned the evaluation results of the anticancer effect evaluation in an environment closer to a living body. Therefore, it is possible to more accurately determine the effectiveness of the treatment for the patient. In addition, in a normal anticancer treatment, only one type of anticancer drug can be administered to a patient at a certain time. However, according to the evaluation system 50 of this embodiment, since a three-dimensional cell structure is used, different types of anticancer drugs can be administered in parallel to cancer cells collected from the same patient, and information on the anticancer effect can be acquired simultaneously. Furthermore, according to the evaluation system 50 of this embodiment, since a three-dimensional cell tissue is used, the cancer cells from which information on the anticancer effect is acquired and the cancer cells from which omics information, etc. are acquired can be made the same. That is, omics information can be acquired from cancer cells having the same omics information as the cancer cells that constitute the three-dimensional cell tissue. This allows the omics information to be accurately associated with information on the anticancer effect. Therefore, it is possible to more accurately determine the effectiveness of the treatment for the patient. Linking omics information with information on anticancer effects in this way is particularly important in predicting the possibility of acquiring resistance, because it is generally known that when cancer cells acquire resistance, the omics information may change compared to before the administration of an anticancer drug.
[0137] In the evaluation system 50 of the embodiment, the cells constituting the stroma in the three-dimensional cell structure may include fibroblasts. In the evaluation system 50 of the embodiment, the cells constituting the stroma in the three-dimensional cell structure may further include vascular endothelial cells, and may further include a vascular network. As a result, the evaluation system 50 of the embodiment can generate a prediction model that learns the evaluation results of the anti-cancer effect evaluation performed in an environment closer to a living body, and achieves the same effect as the above-mentioned effect. In addition, by using a three-dimensional cell structure having a vascular network, the anti-cancer effect of immune cells and an anti-cancer drug can be evaluated in an environment closer to a living body.
[0138] In the evaluation system 50 of the embodiment, the learning information acquisition unit 630 acquires the condition information 620, omics information 621, administration record information 623, and drug information 622 of the subject as learning data. The learning information acquisition unit 630 acquires drug effectiveness information 624 as teacher data. The learning unit 632 generates a prediction model that predicts the effect of an anticancer drug acting on the cancer cells of the subject based on the cancer state of the subject and the omics information of cells collected from the subject. This makes it possible to evaluate the efficacy of the anticancer drug in consideration of various information about the patient, and achieves the same effect as the above-mentioned effect.
[0139] In the evaluation system 50 of the embodiment, the input information acquisition unit 730 acquires, as input information, subject information 720 including condition information on the subject to be predicted and omics information on cells collected from the subject. The prediction unit 733 predicts the effect of an anticancer drug acting on the cancer cells of the subject. As a result, the evaluation system 50 of the embodiment can predict an anticancer drug that is expected to be effective when administered, based on the cancer condition and omics information of the subject, at a stage where the anticancer drug has not yet been administered.
[0140] Moreover, in the evaluation system 50 of the embodiment, the input information acquisition unit 730 acquires, as input information, the target drug information 721. The prediction unit 733 predicts the effect of an anticancer drug specified by the target drug information 721 on cancer cells. As a result, in the evaluation system 50 of the embodiment, it becomes possible to perform so-called screening of new drugs, in which anticancer drugs that are expected to be effective are extracted using the results of evaluating the anticancer effect in an environment closer to a living body.
[0141] In the evaluation system 50 of the embodiment, the input information acquisition unit 730 acquires, as input information, the target drug information 721. The prediction unit 733 predicts the effect of the anticancer drug specified by the target drug information 721 on cancer cells for each cancer state of the patient. This makes it possible for the evaluation system 50 of the embodiment to extract anticancer drugs that are expected to have individual effects according to the cancer state of the patient.
[0142] Moreover, in the evaluation system 50 of the embodiment, the condition information 620 includes information indicating the type of cancer in the subject. The input information acquisition unit 730 acquires the target drug information 721 as input information. The prediction unit 733 predicts the effect of the anticancer drug specified by the target drug information 721 on cancer cells for each type of cancer. As a result, in the evaluation system 50 of the embodiment, a prediction model that predicts the anticancer effect taking into account the type of cancer can be generated, and it becomes possible to extract anticancer drugs that are expected to have individual effects according to the type of cancer.
[0143] In addition, in the evaluation system 50 of the embodiment, the administration record information 623 includes information regarding the combination of multiple anticancer drugs administered to the three-dimensional cell structure. The drug effectiveness information 624 includes the results of judging the anticancer effect of the combination of multiple anticancer drugs administered to the three-dimensional cell structure. The input information acquisition unit 730 acquires, as input information, target drug information 721 corresponding to the combination of multiple anticancer drugs to be predicted. The prediction unit 733 predicts the effect of the combination of anticancer drugs specified by the target drug information 721 on the cancer cells of the subject.
[0144] In general, cancer treatment by drug administration consists of monotherapy, in which only a single anticancer drug is administered, and combination therapy, in which multiple anticancer drugs are administered simultaneously or in sequence to treat the patient using their combined effects. Finding the right combination for combination therapy for each patient is not realistic because the number of combinations of anticancer drugs is enormous. Moreover, there are cases where there are very few patients with similar cancer conditions, and in such cases, it can be even more difficult to find the right combination for combination therapy.
[0145] In contrast, the evaluation system 50 of the embodiment uses a three-dimensional cell structure, and therefore can predict the anticancer effect of a combination of anticancer drugs, taking into account the state of the cancer in the subject. Therefore, it is possible to present to the subject a combination of anticancer drugs that is expected to be effective when the subject undergoes combined treatment, before the anticancer drugs are administered.
[0146] In the evaluation system 50 of the embodiment, the drug effectiveness information 624 includes a result of judging whether or not the cancer cells of the subject have acquired resistance to a predetermined anticancer drug. The input information acquiring unit 730 acquires the subject information 720 of the subject as input information. The prediction unit 733 predicts the degree to which the cancer cells of the subject will acquire resistance to a predetermined anticancer drug.
[0147] In general, when a drug is administered to a patient, the affected area does not necessarily disappear completely, and the cells in the affected area may mutate and acquire resistance to the drug, causing the drug to become ineffective. In particular, when administering an anticancer drug to cancer cells, the cancer cells are prone to mutate, which is one of the factors that make drug administration treatment difficult. In the medical field, although there is an increasing need to predict whether resistance will be acquired, the reality is that no method for predicting this has been realized. In contrast, the evaluation system 50 of the embodiment makes it possible to predict whether the cancer cells of a subject will acquire resistance before administering an anticancer drug.
[0148] In addition, in the evaluation system 50 of the embodiment, the drug effectiveness information 624 includes the result of judging whether or not the cancer cells of the subject have acquired resistance to a specific anticancer drug (first anticancer drug). The administration record information 623 includes information indicating whether or not an anticancer drug (second anticancer drug) different from the specific anticancer drug administered to the cancer cells of the subject has been administered after the cancer cells of the subject have acquired resistance to the specific anticancer drug. The input information acquisition unit 730 acquires the subject information 720 on the subject as input information. The prediction unit 733 predicts the effect of another anticancer drug acting on the cancer cells of the subject after the cancer cells of the subject have acquired resistance to the specific anticancer drug. As a result, in the evaluation system 50 of the embodiment, it is possible to predict an anticancer drug that is expected to be effective when administered after the cancer cells of the subject mutate and the specific anticancer drug becomes ineffective, and it is possible to present an anticancer drug that is expected to be effective even when the cancer cells of the subject acquire resistance to the specific anticancer drug.
[0149] Moreover, the learning device 60 of the embodiment includes a learning information acquisition unit 630 and a learning unit 632. As a result, the learning device 60 of the embodiment achieves the same effects as those described above.
[0150] Moreover, the prediction device 70 of the embodiment includes an input information acquisition unit 730 and a prediction unit 733. As a result, the prediction device 70 of the embodiment achieves the same effects as those described above.
[0151] The evaluation system 50, the learning device 60, and the prediction device 70 in the above-mentioned embodiment may be realized in whole or in part by a computer. In that case, a program for realizing this function may be recorded in a computer-readable recording medium, and the program recorded in the recording medium may be read into a computer system and executed to realize the function. The term "computer system" as used herein includes hardware such as an OS and peripheral devices. The term "computer-readable recording medium" refers to portable media such as flexible disks, optical magnetic disks, ROMs, and CD-ROMs, and storage devices such as hard disks built into a computer system. The term "computer-readable recording medium" may also include a medium that dynamically holds a program for a short period of time, such as a communication line when a program is transmitted via a network such as the Internet or a communication line such as a telephone line, and a medium that holds a program for a certain period of time, such as a volatile memory inside a computer system that is a server or client in that case. The above program may be a program for realizing a part of the above-mentioned function, or may be a program that can realize the above-mentioned function in combination with a program already recorded in the computer system, or may be a program that is realized using a programmable logic device such as an FPGA.
[0152] Although an embodiment of the present invention has been described in detail above with reference to the drawings, the specific configuration is not limited to this embodiment, and designs that do not deviate from the gist of the present invention are also included. [Explanation of symbols]
[0153] 1. Anticancer drug efficacy evaluation system 10...Imaging device 20…Judgment device 30…Patient information DB 40…Drug information database 50…Rating System 60...Learning device 61…Communications Department 62...Storage section 620...Status information 621…Omics information 622…Drug information 623...Administration record information 624…Drug Efficacy Information 625…Prediction model information 63...Control unit 630…Learning Information Acquisition Department 631...Pre-processing section 632…Learning Department 633...Device control section 70…Prediction device 71…Communications Department 72...Storage section 720…Target information 721...Target drug information 722…Prediction model information 73...Control section 730...Input information acquisition unit 731…Prediction target acquisition unit 732…Pre-processing section 733…Prediction Department 734…Post-processing section 735...Device control section
Claims
[Claim 1] A prediction method for predicting an anti-cancer effect performed by a computer device, comprising: an input information acquisition unit acquires input information including information on cancer in a subject to be predicted and drug information of an anticancer drug whose effect on the subject is to be estimated; a prediction unit predicts the possibility that cancer cells in the subject corresponding to the input information will acquire resistance to the anticancer drug, using a correspondence relationship between information on cancer in unspecified subjects, drug information on the anticancer drug, and information indicating whether or not the cancer cells of the subject have acquired resistance to the anticancer drug, the information being obtained by administering the anticancer drug to cells collected from the subject; Forecasting methods.
Citation Information
Patent Citations
Method, computer system, and program for predicting properties of target compounds
JP6567153B1
System for predicting drug effects and adverse effects and program for the same
WO2010064413A1
Method for estimating therapeutic efficacy
WO2018164262A1
Method for evaluating Anti-cancer effect, and method for predicting effectiveness of cancer immunotherapy
WO2019039452A1
Information processing device, control method, and program
WO2019208703A1
Cited By
Seamless can and resin-coated metal sheet for forming seamless can
US12351364B2
